Savara Inc
SVRA3.600USD
0.000
Close 09/18, 16:00（ET）Quotes delayed by 15 min
622.21MMarket Cap
LossP/E TTM
More Details of Savara Inc Company
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Company Info
Ticker SymbolSVRA
Company nameSavara Inc
IPO dateJun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
Number of employees59
Security typeOrdinary Share
Fiscal year-endJun 25
Address6836 Bee Cave Road
CityAUSTIN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code78746
Phone151285113796
Websitehttps://savarapharma.com/
Ticker SymbolSVRA
IPO dateJun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Aug 13
Updated: Wed, Aug 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.37%
Other
55.50%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.37%
Other
55.50%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.10%
Venture Capital
20.77%
Hedge Fund
19.72%
Investment Advisor/Hedge Fund
15.96%
Private Equity
6.63%
Corporation
2.71%
Individual Investor
2.67%
Research Firm
0.54%
Bank and Trust
0.31%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
295
181.81M
105.19%
-8.48M
2025Q1
306
176.74M
102.29%
-9.64M
2024Q4
294
173.80M
101.27%
-5.45M
2024Q3
274
169.68M
103.28%
+3.87M
2024Q2
257
157.29M
95.89%
+28.15M
2024Q1
230
131.01M
94.21%
-92.17K
2023Q4
197
123.19M
91.03%
-2.15M
2023Q3
177
120.11M
89.27%
+14.67M
2023Q2
170
92.45M
81.05%
-2.68M
2023Q1
166
87.31M
76.55%
-5.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
24.47M
14.16%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
17.60M
10.18%
+3.04M
+20.84%
Mar 31, 2025
TCG Crossover Management, LLC
12.36M
7.15%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
11.46M
6.63%
+2.80M
+32.35%
Mar 31, 2025
Vestal Point Capital, LP
11.00M
6.36%
+225.00K
+2.09%
Mar 31, 2025
VR Adviser, LLC
3.26M
1.88%
+3.26M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.71M
5.04%
+229.91K
+2.71%
Mar 31, 2025
The Vanguard Group, Inc.
8.10M
4.69%
-190.72K
-2.30%
Mar 31, 2025
Nantahala Capital Management, LLC
8.08M
4.67%
+550.12K
+7.31%
Mar 31, 2025
Deerfield Management Company, L.P.
7.96M
4.61%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
